The Warning Changed. What Actually Changed With It?

The question

I heard the FDA changed the warning on menopause hormone therapy. Does that mean it is now safe for everyone? Can it protect my heart?

The simple answer

The warning changed. Hormone therapy did not become risk-free.

On February 12, 2026, the FDA approved updated labels for a first group of six menopause hormone-therapy products. Statements about heart disease, breast cancer, and probable dementia were removed from the boxed warning, the most prominent warning on a prescription label.

The FDA did not remove the heart-disease and breast-cancer information from the full prescribing labels. Those risks remain in the Warnings and Precautions sections. The boxed warning about cancer of the uterine lining also remains on estrogen-alone products that travel throughout the body when used by a woman who has a uterus.

Hormone therapy can be a reasonable treatment for menopause symptoms for many women. The label change did not make it right for every woman, and hormone therapy is not prescribed simply to prevent a heart attack.

What we know

Hormone therapy remains the most effective treatment for bothersome hot flashes and night sweats. Some products can also help with vaginal symptoms or prevent bone loss.

For many healthy women with symptoms who are younger than 60 or within 10 years of menopause, the balance of benefits and risks is often favorable. That is a starting point for a personal conversation, not an automatic yes.

The exact product matters. A pill, patch, gel, and low-dose vaginal product do not all travel through the body in the same way. Their uses and risks should not be treated as interchangeable.

• If you still have a uterus and use estrogen that travels throughout the body, you generally also need progesterone or a related medicine to protect the uterine lining.
• Low-dose vaginal estrogen mostly works where it is used. It is different from treatment intended to reach the whole body.
• Unexplained vaginal bleeding or a history of breast cancer, another cancer affected by estrogen, blood clots, stroke, heart attack, or liver disease can change the decision. The exact product label and your full history matter.
• FDA-approved and compounded products do not go through the same review. ACOG advises against routinely choosing a compounded hormone when an FDA-approved option is available.

What we do not know yet

We do not have equally strong long-term evidence for every hormone, dose, delivery method, or combination.

Some studies that followed women in usual care suggest that estrogen taken through the skin may carry a lower blood-clot risk than estrogen taken by mouth. Because women were not assigned at random to one form or the other, that pattern does not prove that one form is safest for every woman.

There is also less trial evidence for women who begin hormone therapy after age 60, more than 10 years after menopause, or continue it for many years.

A label change cannot answer whether hormone therapy is right for one woman. Symptoms, age, time since menopause, whether she has a uterus, the exact product, and her personal history still shape the decision.

Why this matters to your heart

Hormone therapy may help with symptoms, sleep, and daily function. Those benefits matter.

It still does not replace checking blood pressure, cholesterol, and blood sugar or discussing smoking, fitness, family history, and pregnancy complications. It should not be started simply to prevent heart disease.

Your hormone decision belongs inside your full heart story. So do the form of treatment, when you start it, and what was already present in your history.

The warning changed. Your history still matters.

One question to ask your clinician

Given my symptoms, age, time since menopause, and personal heart and cancer history, is hormone therapy reasonable for me, and would the form I use change my risks?